Introduction: Heberprot-P, considered the medicine of the 21st century for the healing of diabetic feet, is emerging as a promising technique for the repair of destroyed or damaged tissues. Objective: To present the results of the use of intra- and perilesional Heberprot-P in complex ulcers in the province of Pinar del Rio, Cuba from 2022 to 2024. Methods: a descriptive, retrospective, cross-sectional study of the use of Heberprot-P 75 mcg was developed. intra and perilesional in patients with complex ulcers from January 2022 to March 2024 in the province Pinar del Río, Cuba, with a total of 8482 lesions and an intentional sample of 181 complex ulcers. Inclusion criteria: presence of complex ulcers in the lower limbs. Exclusion criteria: those who did not meet the inclusion criteria with prior signing of the informed consent. Results: non-complex ulcers were more frequent, for 98%, diabetic foot represented 81% of complex ulcers, these with a higher rate of major amputation, hospitalization and intralesional infiltrations, with 18 doses (6 weeks, 42 days ) to achieve total granulation, correspondingly the time for closure by secondary intention was longer, 6 weeks after its application (84 days in total). Conclusions: the use of intra- and perilesional Heberprot-P is an effective therapy to accelerate granulation and closure by secondary intention of complex wounds that are difficult to heal.
Read full abstract